Biotech

Eyenovia (NASDAQ:EYEN) a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced the pricing of its initial public offering of 2,730,000 shares of common stock at a price of $10.00 per share. As quoted in the press release: The gross proceeds …

Eyenovia (NASDAQ:EYEN) a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced the pricing of its initial public offering of 2,730,000 shares of common stock at a price of $10.00 per share.
As quoted in the press release:

The gross proceeds to Eyenovia from the initial public offering are expected to be $27.3 million, before underwriting discounts and commissions and other estimated offering expenses. The shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “EYEN” on January 25, 2018. The offering is expected to close on January 29, 2018, subject to customary closing conditions.

Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE American:LTS) and Roth Capital Partners are acting as joint book-running managers for the offering.

Click here to read the full press release.

MARKETS

Markets
TSX19062.91+345.79
TSXV647.33+15.54
DOW31500.68+823.32
S&P 5003911.74+116.01
NASD11607.62+375.43
ASX6528.40+19.90

COMMODITIES

Commodities
Gold1827.54+0.47
Silver21.15+0.03
Copper3.740.00
Palladium1879.51+6.50
Platinum911.26+4.32
Oil107.06+2.79
Heating Oil4.24+0.02
Natural Gas6.17-0.07

DOWNLOAD FREE REPORTS

×